TELATELAHealthcare · Medical Devices

TELA Stock Forecast: TELA Bio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.69
−5.30% on the day

The median 12-month analyst price target for TELA Bio, Inc. is $2. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$32.8M
Ticker Nerd rank
36/ 100
Median analyst target
$2.00
Analysts covering
3
Revenue$19.3M−4.5% y/y
Operating income−$9.3M
Net income−$11.3M
Free cash flow−$9.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.0%
1M
−36.8%
YTD
−41.7%
1Y
−35.0%
From 52W high
−51.2%
From 52W low
+22.9%
$0.56
$1.41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores TELA Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
36/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
82
Growth
53
Revisions
48
Momentum
41
Quality
37
Value
26
Volatility
22
Issuance
8

Accruals (82): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TELA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TELA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00Jan 26Apr 26Jul 26Oct 26TELAHigh $2.00Median $2.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$2.00
Low
$2.00
Median
$2.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
25 Sept 2026Craig-HallumInitiatesBuy$2.00
27 Mar 2026CitizensMaintainsMarket Outperform$5.00 → $3.00
25 Mar 2026Canaccord GenuityMaintainsBuy$4.00 → $2.00
25 Mar 2026Lake StreetMaintainsBuy$3.00 → $2.00
25 Mar 2026Piper SandlerMaintainsNeutral$1.25 → $1.00
1 Dec 2025Lake StreetMaintainsBuy—
18 Nov 2025Canaccord GenuityMaintainsBuy—
14 Nov 2025CitizensMaintainsMarket Outperform—
14 Nov 2025Piper SandlerReiteratesNeutral—
21 Mar 2025Canaccord GenuityMaintainsBuy—
21 Mar 2025Citizens Capital MarketsMaintainsMarket Outperform—
21 Mar 2025Piper SandlerDowngradeNeutral—
8 Nov 2024Piper SandlerMaintainsOverweight—
4 Oct 2024Canaccord GenuityMaintainsBuy—
13 Aug 2024Canaccord GenuityMaintainsBuy—
13 Aug 2024JMP SecuritiesMaintainsMarket Outperform—
13 Aug 2024Lake StreetMaintainsBuy—
13 Aug 2024Piper SandlerMaintainsOverweight—
25 July 2024Canaccord GenuityMaintainsBuy—
10 May 2024Piper SandlerReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TELA.

Market Radar

This page is one stock. Monday covers all of them.

TELA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TELA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, TELA Bio, Inc. returned −35.0% against +6.9% for the S&P 500, dividends included.

TELA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26TELAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TELA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
4
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.5×

Cheaper than 80% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−8.4%

Higher than 18% of US stocks

Earnings growth (YoY)
—
Gross margin
72.3%

Higher than 85% of US stocks

Operating margin
−40.5%

Higher than 19% of US stocks

Net margin
−53.6%

Higher than 10% of US stocks

Returns & dividend
Return on equity
—
Return on assets
−35.6%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TELA Bio, Inc. has a market value of $32.8M and an enterprise value of $68.2M.

  • Revenue in the twelve months to 30 June 2026: $79.9M. The latest quarter shrank 4.5% year on year.

  • Net income over the same four quarters: −$41.2M, a −51.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.77.

  • Free cash flow in the twelve months to 30 June 2026: −$31.6M.

  • Shares outstanding: 44.8M.

  • TELA Bio, Inc. employs 218 people — $367K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

TELA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TELATELA Bio, Inc.$32.8M36
MYOMyomo, Inc.$32.1M62
XTNTXtant Medical Holdings, Inc.$29.5M51
NSYSNortech Systems, Inc.$29.4M82
NSPRInspireMD, Inc.$29.2M73
MDAISpectral AI, Inc.$33.5M26
QTIQT Imaging Holdings, Inc.$28.1M20

Take a look at TELA’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own TELA Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TELA

What is the TELA stock price forecast for 2026-2027?

The median 12-month analyst price target for TELA Bio, Inc. is $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TELA stock a buy right now?

Of the 3 analysts covering TELA Bio, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TELA Bio, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TELA?

As at 21 Nov 2026, TELA Bio, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (82 of 100).

Will TELA stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $2, and Ticker Nerd's factor model ranks TELA Bio, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TELA stock forecast for 2030?

No analyst covering TELA Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TELA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.

How has TELA stock performed over the past year?

TELA Bio, Inc. returned -35.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TELA Bio, Inc. do?

TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions for surgeons and healthcare providers. The company develops and markets reinforced tissue matrix products designed for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery, with an emphasis on preserving and restoring the patient’s own anatomy.

Company

About TELA Bio, Inc.

TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions for surgeons and healthcare providers. The company develops and markets reinforced tissue matrix products designed for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery, with an emphasis on preserving and restoring the patient’s own anatomy. Its OviTex portfolio includes products for open, laparoscopic, and robotic procedures, as well as configurations tailored to different surgical needs in general surgery and reconstructive care. TELA Bio also supports applications that aim to reduce reliance on permanent synthetic materials while leveraging the body’s natural healing response. Headquartered in Malvern, Pennsylvania, TELA Bio serves the medical device market through products that address unmet needs in modern soft-tissue repair.

CEO Ms. Heather C. Getz CPA, M.B.A. · 218 employees · United States · https://www.telabio.com